The study showed that patients taking semaglutide were 24% less likely to experience major kidney problems compared to those taking a placebo, and they also had a lower risk of death
However, it has become important to confirm the clinical relevance and durability of the potential benefits in different population groups who are not necessarily required to lose weight through well-designed and adequately powered trials
focus on preconception optimizationfolate, glycemic control, smoking/alcohol cessation, weight management, and medication review
If you have recently begun a medication like tirzepatide a dual-acting GLP-1 and GIP receptor agonistyou may be noticing physical sensations that feel unfamiliar
Stress and circulating cell-free mitochondrial DNA: a systematic review of human studies, physiological considerations, and technical recommendations